987 Protocol Driven Reduction of Haematoma Following Symptomatic Carotid Endarterectomy (CEA) – a Prospective Cohort Study. (19th August 2022)

• Record Type: Journal Article
• Authors: Marzouqa, N; Jacob, L; Busuttil, A; Baker, D
• Is Part Of: British journal of surgery. Volume 109(2022)Supplement 6
• Publication Date: 2022-08-19
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1093/bjs/znac269.539
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Aim: Stroke is the third leading cause of death in developed nations and the leading cause of long-term disability. Carotid artery stenosis accounts for 20 to 30% of ischaemic strokes. Carotid Endarterectomy, has proven highly effective in preventing the development of strokes, TIAs and reducing death among patients with symptomatic carotid artery stenosis of 50–99%. The most common complication of CEA is wound haematomas. This study evaluates a protocol driven haemostasis pathway aimed to address the findings of a recent QI project that identified a significantly high neck haematoma rate as well as a high return to theatre rate for the complication. Method: A prospective cohort outcome study between June 2019 and June 2020 was conducted, with the introduction of this stepwise pathway introduced as a quality improvement measure. Patch haemostasis ensured with attention to bleeding points. 10 minutes light compression applied – activated clotting time checked/ protamine given if required. 10 minutes post protamine - 1 g tranexamic acid administered if needed. If bleeding persists after 10 minutes, discussed with haematology / platelet transfusion. This was implemented at the end of successful patch closure, for each CEA. Results: Post-CEA haematoma rates decreased from 7% to 3.6%. Return to theatre rates reduced from 6% to 0.9% with no increase in peri-operative stroke rates. Conclusion: Our protocol appears to reduce post-CEA haematoma rates. Return to theatre rates had also dropped without an increase in peri-operative stroke rates despite using protamine and tranexemic acid when needed.